
    
      Eligible participants for this study must have a diagnosis of probable AD and must have
      clinically meaningful agitation secondary to AD.

      This is a multicenter, randomized, placebo-controlled study, consisting of 12 weeks of
      treatment.

      Approximately 470 participants will be enrolled at approximately 75 centers in North America.

      Study medication will be administered orally twice-daily from Day 1 through Day 85. Screening
      will occur within approximately 4 weeks prior to randomization. Following screening
      procedures for assessment of inclusion and exclusion criteria, eligible participants will be
      randomized into the study.
    
  